D-0070-2022 Class III Terminated

Recalled by Ultra Seal Corporation — New Paltz, NY

FDA drug recall D-0070-2022 was initiated by Ultra Seal Corporation on Oct 13, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid. The recall status is terminated (terminated Mar 28, 2022). Affected quantity: 2,484,274 tablets.

Recall details

Product Type
Drugs
Report Date
Nov 3, 2021
Initiation Date
Oct 13, 2021
Termination Date
Mar 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,484,274 tablets

Product description

PainAway II (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets , 2 tablets/pk, packaged in 12,000 Packets/Case, Material # 11161, Mfg. for Respond Industries First Aid, Mason, OH 45040 (Shipping Label)

Reason for recall

Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: AK-9336, exp. date 21-Oct; K9406, AK-9407, exp. date 21-Dec; K-9860, exp. date 22-Oct; AK-1057, exp. date 23-Feb

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0070-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0070-2022. Report a data issue: hello@regdatalab.com.